HemoCue

Executive Summary

HemoCue is a Swedish point-of-care diagnostics company with over four decades of experience in hematology and diabetes testing. Its portable, laboratory-accurate systems serve diverse clinical settings, from hospitals to remote field clinics. With a strong foothold in hemoglobin screening and a growing diabetes portfolio, HemoCue benefits from the global push toward decentralized, rapid diagnostics. The company's ability to deliver reliable results outside traditional labs positions it well for expansion in emerging markets and chronic disease management. While privately held, HemoCue's established brand and sustained innovation underpin its competitive advantage in the POC segment.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation hemoglobin analyzer with enhanced connectivity60% success
• Q1 2027FDA clearance for a new diabetes monitoring test (e.g., HbA1c POC assay)50% success
• Q2 2026Strategic partnership with a major hospital group for distribution in Asia-Pacific70% success